NeuraLight Presents Results on Parkinson’s Progression at IAPRD 2025

Our CEO Edmund Ben-Ami and VP of Clinical Partnerships Eitan Raveh, PhD, presented new clinical findings on “Monitoring Parkinson’s Progression: Eye Movements vs. MDS-UPDRS III”  at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025), on May 7–10, 2025, in New York City.

Study Overview

• Cohort: 30 patients with early Parkinson’s disease (H&Y ≤ 2) and 50 matched controls
• Design: 9-month follow-up longitudinal trial with 4 visits
• Method: Eye movements quantified via NeuraLight’s software-based, computer vision platform

Key Findings

• Significant progression in hypometric saccades detected within 9 months (p < 0.0003)
• No measurable change in healthy controls
• MDS-UPDRS III scores remained unchanged over the same period
• Simulated trial modeling showed potential to cut required patient numbers by >50% (360 → 140 per arm) and shorten trial duration (21 → 9 months)

Conclusion

Eye-movement biomarkers demonstrated greater sensitivity than MDS-UPDRS III in detecting Parkinson’s disease progression, supporting their use as efficient and reproducible endpoints in trials of disease-modifying therapies.

Full abstract available in Parkinsonism & Related Disorders here.